CSIMarket Company Name, Ticker, Competitors, else..
 
Cidara Therapeutics Inc   (NASDAQ: CDTX)
 
Price: $221.3800 $0.06 0.027%
Day's High: $221.41 Week Perf: 0.26 %
Day's Low: $ 221.25 30 Day Perf: 0.4 %
Volume (M): 2,691,000 52 Wk High: $ 221.42
Volume (M$): $ 595,734 52 Wk Avg: $147.25
Open: $221.32 52 Wk Low: $61.10



 Market Capitalization (Millions $) 5,951
 Shares Outstanding (Millions) 27
 Employees 69
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -148
 Cash Flow (TTM) (Millions $) 173
 Capital Exp. (TTM) (Millions $) 0

Business Description


Cidara Therapeutics Inc is a biotechnology company focused on developing and commercializing novel antifungal and immunotherapy technologies. The company's goal is to address unmet medical needs in the treatment of serious fungal infections and provide innovative solutions for patients with compromised immune systems. Cidara's proprietary technology platforms, CloudbreakTM and Immunotherapy Platforms, aim to improve patient outcomes and reduce the risks associated with existing antifungal therapies. The company is committed to advancing its pipeline of drug candidates and revolutionizing the field of infectious diseases.


   Company Address: 6310 Nancy Ridge Drive, San Diego, 92121 CA
   Company Phone Number: 752-6170   Stock Exchange / Ticker: NASDAQ CDTX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
GILD        3.65% 
AMPH        5.32% 
AVIR        8.77% 
AZN      0% 
PFE        1.75% 
RCUS        1.54% 
• View Complete Report
   



Clinical Study

Cidara Therapeutics, Inc. (Nasdaq CDTX), a pioneering biotechnology company known for its innovative Cloudb...

Published Tue, Oct 14 2025 8:39 AM UTC

Cidara Therapeutics Set to Showcase Promising Data for CD388 at ID Week 2025 amid Challenging Financial Landscape Cidara Therapeutics, Inc. (Nasdaq: CDTX), a pioneering biotechnology company known for its innovative Cloudbreak platform responsible for advancing drug-Fc conjugate (DFC) therapeutics, is preparing to present late-breaking Phase 2 clinical data on its antiviral ...
Clinical Study

Cidara Therapeutics Embarks on Phase 3 ANCHOR Trial for CD388 A Pioneering Approach to Influenza Prevention in High-R...

Published Fri, Sep 26 2025 9:41 AM UTC

In a significant development within the realm of infectious disease management, Cidara Therapeutics has announced the commencement of its Phase 3 ANCHOR trial, which aims to evaluate the efficacy of CD388 in preventing seasonal influenza among high-risk populations. This important milestone marks the beginning of an ambitious study expected to enroll approximately 6,000 part...
Shares

Cidara Therapeutics Grants New Employee Stock Options: Analyzing the Impact on Shareholders

Published Fri, Oct 4 2024 8:30 PM UTC

In recent news, Cidara Therapeutics, Inc. (Nasdaq: CDTX), a pioneering biotechnology firm renowned for its innovative Cloudbreak platform, announced the allocation of stock options and restricted stock units (RSUs) to Dipesh Bhatt, a new key employee. Utilizing drug-Fc conjugate (DFC) immunotherapies, the company aims to enhance life-saving treatments for severe diseases. Th...
Clinical Study

Cidara Therapeutics Bold Moves Pioneering Influenza Treatment with CD388 and the Cloudbreak® Platform,

Published Wed, Sep 25 2024 12:00 PM UTC

Cidara Therapeutics, Inc. has recently announced pivotal steps in its strategic focus on the development of CD388, an innovative drug-Fc conjugate (DFC) candidate aimed at combating influenza A and B. This comprehensive review delves into the data presented at the OPTIONS XII for the Control of Influenza Conference, outlining the safety and pharmacokinetics of CD388. Additi...
Clinical Study

Cidara Therapeutics Marks Milestones with NAVIGATE Trial Kickoff and Strategic Rezafungin Divestiture,

Published Mon, Sep 23 2024 12:01 PM UTC

Cidara Therapeutics Advances with NAVIGATE Trial and Strategic Divestiture DecisionCidara Therapeutics, Inc. (Nasdaq: CDTX), a pioneering biotechnology company, has recently set significant milestones in its strategic trajectory, including the initiation of a Phase 2b clinical trial and the divestiture of one of its key assets. NAVIGATE Trial for Seasonal Influenza On April...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 14.09
PEG (TTM) -

Financial Strength Current
Quick Ratio 4.38
Working Capital Ratio 4.62
Leverage Ratio (MRQ) 0.23
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -8.86 $
Revenues (TTM) -
Cash Flow (TTM) 6.42 $
Cash 15.62 $
Book Value 15.71 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -2,150,957
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.